WO1997032572A3 - Materials and methods for enhancing cellular internalization - Google Patents

Materials and methods for enhancing cellular internalization Download PDF

Info

Publication number
WO1997032572A3
WO1997032572A3 PCT/US1997/003276 US9703276W WO9732572A3 WO 1997032572 A3 WO1997032572 A3 WO 1997032572A3 US 9703276 W US9703276 W US 9703276W WO 9732572 A3 WO9732572 A3 WO 9732572A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivered
compositions
cell
agents
interacts
Prior art date
Application number
PCT/US1997/003276
Other languages
French (fr)
Other versions
WO1997032572A9 (en
WO1997032572A2 (en
Inventor
David A Edwards
Daniel R Deaver
Robert S Langer
Original Assignee
Penn State Res Found
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Res Found, Massachusetts Inst Technology filed Critical Penn State Res Found
Priority to JP9531869A priority Critical patent/JP2000506165A/en
Priority to EP97908818A priority patent/EP0885002B1/en
Priority to AT97908818T priority patent/ATE508733T1/en
Priority to PT97908818T priority patent/PT885002E/en
Priority to DK97908818.4T priority patent/DK0885002T3/en
Priority to ES97908818T priority patent/ES2395214T3/en
Priority to AU20631/97A priority patent/AU2063197A/en
Publication of WO1997032572A2 publication Critical patent/WO1997032572A2/en
Publication of WO1997032572A3 publication Critical patent/WO1997032572A3/en
Publication of WO1997032572A9 publication Critical patent/WO1997032572A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Abstract

Compositions and methods for delivering agents across cell membranes are disclosed. The compositions include an agent to be delivered, a viscous material, such as a hydrogel, lipogel or viscous sol, and, optionally, a carrier that includes a ligand that binds to or interacts with cell surface receptors. The agent to be delivered binds to or otherwise interacts with cell surface receptors, is attached, either covalently or ionically to a molecule that binds to or interacts with a cell surface receptor, or is associated with the carrier. Agents to be delivered include bioactive compounds and diagnostic agents. The compositions have an apparent viscosity roughly equal to the viscosity of the cytosol in the cell to which the agent is to be delivered. The rate of cellular internalization is higher when the viscosity of the viscous material and that of the cytosol in the cell are approximately the same, relative to when they are not the same. The compositions enhance cellular entry of bioactive agents and diagnostic materials when administered vaginally, nasally, rectaly ocularly, orally, or to the respiratory or pulmonary system.
PCT/US1997/003276 1996-03-04 1997-03-03 Materials and methods for enhancing cellular internalization WO1997032572A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP9531869A JP2000506165A (en) 1996-03-04 1997-03-03 Materials and Methods for Enhancing Cell Internalization
EP97908818A EP0885002B1 (en) 1996-03-04 1997-03-03 Materials and methods for enhancing cellular internalization
AT97908818T ATE508733T1 (en) 1996-03-04 1997-03-03 MATERIALS AND METHODS FOR INCREASE CELLULAR INTERNALIZATION
PT97908818T PT885002E (en) 1996-03-04 1997-03-03 Materials and methods for enhancing cellular internalization
DK97908818.4T DK0885002T3 (en) 1996-03-04 1997-03-03 Materials and methods for enhancing cellular internalization
ES97908818T ES2395214T3 (en) 1996-03-04 1997-03-03 Materials and methods to increase cellular internalization
AU20631/97A AU2063197A (en) 1996-03-04 1997-03-03 Materials and methods for enhancing cellular internalization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1272196P 1996-03-04 1996-03-04
US60/012,721 1996-03-04

Publications (3)

Publication Number Publication Date
WO1997032572A2 WO1997032572A2 (en) 1997-09-12
WO1997032572A3 true WO1997032572A3 (en) 1997-11-27
WO1997032572A9 WO1997032572A9 (en) 1997-12-31

Family

ID=21756381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/003276 WO1997032572A2 (en) 1996-03-04 1997-03-03 Materials and methods for enhancing cellular internalization

Country Status (9)

Country Link
US (1) US5985320A (en)
EP (1) EP0885002B1 (en)
JP (1) JP2000506165A (en)
AT (1) ATE508733T1 (en)
AU (1) AU2063197A (en)
DK (1) DK0885002T3 (en)
ES (1) ES2395214T3 (en)
PT (1) PT885002E (en)
WO (1) WO1997032572A2 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9139642B2 (en) 2010-07-09 2015-09-22 Crucell Holland B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US9481736B2 (en) 2009-03-05 2016-11-01 Abbvie, Inc. IL-17 binding proteins
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US9592293B2 (en) 2006-09-08 2017-03-14 Abbvie Inc. Interleukin-13 binding proteins
US11849741B2 (en) 2015-10-20 2023-12-26 Savage River, Inc. Meat-like food products

Families Citing this family (273)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972707A (en) * 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
IT1289608B1 (en) * 1997-02-05 1998-10-15 Angelini Ricerche Spa COMPOSITION FOR THERAPEUTIC OR DIAGNOSTIC USE ADMINISTRABLE VIA INTRANASAL, SUBLINGUAL OR VAGINAL
US6593369B2 (en) 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
WO2000019978A2 (en) 1998-10-05 2000-04-13 The Penn State Research Foundation Compositions and methods for enhancing receptor-mediated cellular internalization
US20050153926A1 (en) * 1998-12-04 2005-07-14 Adams Christopher P. Method for the immobilization of oligonucleotides
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
WO2000061597A1 (en) 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
AU2002219944B2 (en) 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DE60142614D1 (en) 2000-01-27 2010-09-02 Medimmune Inc INITÄT
US6262020B1 (en) * 2000-02-15 2001-07-17 Alphamed Pharmaceuticals Corp. Topical wound therapeutic compositions
DK1259547T3 (en) 2000-03-01 2012-10-15 Medimmune Inc HIGH POTENTIAL, RECOMBINANT ANTIBODIES AND PROCEDURE FOR PRODUCING THEM
EP1309904A4 (en) * 2000-03-03 2006-03-29 Valentis Inc Improved poloxamer and poloxamine compositions for nucleic acid delivery
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
WO2003046144A2 (en) * 2001-11-26 2003-06-05 Molecular Reflections, Inc. Microscale immobilization of molecules using a hydrogel and methods of use thereof
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP1534327A4 (en) * 2002-07-25 2006-08-23 Medimmune Inc Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
EP2371389A3 (en) 2002-08-14 2012-04-18 MacroGenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
DE60336406D1 (en) 2002-10-16 2011-04-28 Purdue Pharma Lp ANTIBODIES BINDING TO CELL ASSOCIATED CA 125 / 0722P, AND METHOD FOR THEIR USE
US7483738B2 (en) * 2002-11-29 2009-01-27 Power Paper Ltd. Combination stimulating and exothermic heating device and method of use thereof
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2272533A1 (en) 2003-01-13 2011-01-12 MacroGenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
WO2004078213A1 (en) * 2003-03-06 2004-09-16 Chikako Nishigori Composition for target substance introduction and method of target substance introduction
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
EP1635762B1 (en) * 2003-06-13 2021-03-03 Civitas Therapeutics, Inc. Low dose pharmaceutical powders for inhalation
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
DK1684782T3 (en) * 2003-10-03 2015-11-02 Thorn Bioscience Llc PROCEDURE FOR SYNCHRONIZING OVULATION FOR TEMPORARY REGULATED BREEDING WITHOUT BROWN DETECTION
US20070292494A1 (en) * 2004-03-19 2007-12-20 Let There Be Hope Medical Research Institute Carbohydrate-Derivatized Liposomes for Targeting Cellular Carbohydrate Recognition Domains of Ctl/Ctld Lectins, and Intracellular Delivery of Therapeutically Active Compounds
WO2006015302A1 (en) * 2004-07-29 2006-02-09 X-Sten, Corp. Spinal ligament modification devices
US20080020466A1 (en) * 2004-08-17 2008-01-24 Bml, Inc. Detection Method Using Detecting Device
CA2580921C (en) 2004-09-21 2016-04-12 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP1812068A4 (en) * 2004-10-29 2010-06-09 Medimmune Inc Methods of preventing and treating rsv infections and related conditions
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
US20070003528A1 (en) * 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
US7700739B2 (en) * 2005-06-30 2010-04-20 Abbott Laboratories IL-12/p40 binding proteins
WO2007016686A2 (en) 2005-07-29 2007-02-08 Vertos Medical, Inc. Percutaneous tissue excision devices and methods
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
CN101370525B (en) 2005-08-19 2013-09-18 Abbvie公司 Dual variable domain immunoglobin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500359A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2542501T3 (en) 2005-09-30 2015-08-06 Abbvie Deutschland Gmbh & Co Kg Protein binding domains of the protein family of repulsive targeting molecules (RGM) and functional fragments thereof, as well as their use
CN102898519B (en) 2005-11-30 2015-10-28 Abbvie公司 Monoclonal antibody of anti-amyloid beta protein and uses thereof
US7942830B2 (en) 2006-05-09 2011-05-17 Vertos Medical, Inc. Ipsilateral approach to minimally invasive ligament decompression procedure
EP2505209A1 (en) 2006-06-26 2012-10-03 MacroGenics, Inc. Fcgamma-RIIB-specific antibodies and methods of the use thereof
BRPI0716088B8 (en) 2006-08-28 2021-05-25 Kyowa Hakko Kirin Co Ltd isolated antibody, composition, isolated nucleic acid molecule, vector, method for producing an antibody, hybridoma, and kit
EP2064335A4 (en) 2006-10-16 2011-03-30 Medimmune Llc Molecules with reduced half-lives, compositions and uses thereof
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
SG194368A1 (en) 2007-05-04 2013-11-29 Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa Engineered rabbit antibody variable domains and uses thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
PE20090329A1 (en) * 2007-05-30 2009-03-27 Abbott Lab HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CA2694488A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
BRPI0907046A2 (en) 2008-01-18 2015-07-28 Medimmune Llc Engineered cysteine antibody, isolated nucleic acid, vector, host cell, antibody conjugate, pharmaceutical composition, methods of detecting cancer, autoimmune, inflammatory or infectious disorders in an individual and inhibiting proliferation of a target cell
AU2009236459B2 (en) * 2008-04-14 2013-07-25 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5890174B2 (en) 2008-05-09 2016-03-22 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Antibody against terminal glycation end product receptor (RAGE) and use thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
RU2010153580A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
MX2010014574A (en) 2008-07-08 2011-04-27 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof.
BRPI0915825A2 (en) 2008-07-08 2015-11-03 Abbott Lab prostaglandin binding proteins and uses thereof
USD611146S1 (en) 2008-10-23 2010-03-02 Vertos Medical, Inc. Tissue modification device
USD619252S1 (en) 2008-10-23 2010-07-06 Vertos Medical, Inc. Tissue modification device
USD610259S1 (en) 2008-10-23 2010-02-16 Vertos Medical, Inc. Tissue modification device
USD619253S1 (en) 2008-10-23 2010-07-06 Vertos Medical, Inc. Tissue modification device
USD621939S1 (en) 2008-10-23 2010-08-17 Vertos Medical, Inc. Tissue modification device
US20100233079A1 (en) * 2008-12-04 2010-09-16 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN106220734A (en) 2008-12-19 2016-12-14 宏观基因有限公司 Covalent diabodies and application thereof
BRPI1007371A2 (en) * 2009-01-29 2018-03-27 Abbott Lab il-1 binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
US8905913B2 (en) 2009-04-23 2014-12-09 Jbs United Animal Health Ii Llc Method and composition for synchronizing time of insemination
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
JP5918129B2 (en) 2009-06-22 2016-05-18 メディミューン，エルエルシー Engineered Fc region for site-specific conjugation
KR101778317B1 (en) 2009-08-13 2017-09-13 얀센 백신스 앤드 프리벤션 비.브이. Antibodies against human respiratory syncytial virus(rsv) and methods of use
CN105131112A (en) 2009-08-29 2015-12-09 Abbvie公司 Therapeutic dll4 binding proteins
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2486141B1 (en) 2009-10-07 2018-01-10 MacroGenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
CN102666875A (en) 2009-10-15 2012-09-12 雅培制药有限公司 Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
AU2010329955A1 (en) 2009-12-08 2012-05-24 Abbott Gmbh & Co. Kg Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
KR20180044441A (en) 2010-03-02 2018-05-02 애브비 인코포레이티드 Therapeutic dll4 binding proteins
NZ602054A (en) 2010-03-17 2014-10-31 Abbott Res Bv Anti-nerve growth factor (ngf) antibody compositions
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
CA2800206C (en) 2010-06-25 2018-06-05 (Inserm) Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of respiratory tract infections
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
EP2601216B1 (en) 2010-08-02 2018-01-03 MacroGenics, Inc. Covalent diabodies and uses thereof
PE20131412A1 (en) 2010-08-03 2014-01-19 Abbvie Inc IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
CN103080134B (en) 2010-08-20 2015-11-25 诺华股份有限公司 The antibody of EGF-R ELISA 3 (HER3)
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
PE20141060A1 (en) 2010-12-21 2014-09-26 Abbvie Inc IL-1 ALPHA AND BETA DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND THEIR USE
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
HUE037651T2 (en) 2011-04-20 2018-09-28 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
AU2012259162C1 (en) 2011-05-21 2020-05-21 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
AU2012283039A1 (en) 2011-07-13 2014-01-30 Abbvie Inc. Methods and compositions for treating asthma using anti-IL-13 antibodies
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
JP6120848B2 (en) 2011-08-15 2017-04-26 メディミューン，エルエルシー Anti-B7-H4 antibody and use thereof
TW201323440A (en) 2011-10-24 2013-06-16 Abbvie Inc Immunobinders directed against sclerostin
CN107233569B (en) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 Antibody formulations and methods
SG11201402739YA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
US20130251703A1 (en) 2011-12-05 2013-09-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
EP2791173B1 (en) 2011-12-14 2020-07-29 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP2791175A2 (en) 2011-12-14 2014-10-22 Abbvie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TW201333035A (en) 2011-12-30 2013-08-16 Abbvie Inc Dual specific binding proteins directed against IL-13 and/or IL-17
KR102129234B1 (en) 2012-01-27 2020-07-02 아비에 도이치란트 게엠베하 운트 콤파니 카게 Composition and method for the diagnosis and treatment of disease associated with neurite degeneration
WO2013184514A1 (en) 2012-06-04 2013-12-12 Irm Llc Site-specific labeling methods and molecules produced thereby
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
WO2014011955A2 (en) 2012-07-12 2014-01-16 Abbvie, Inc. Il-1 binding proteins
KR20190107184A (en) 2012-11-01 2019-09-18 애브비 인코포레이티드 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
MX2015005874A (en) 2012-11-09 2015-09-10 Pfizer Platelet-derived growth factor b specific antibodies and compositions and uses thereof.
DK2925339T3 (en) 2012-11-28 2020-07-20 United Ah Ii Llc Method for synchronizing insemination time in gilts
BR112015014063A2 (en) 2012-12-19 2018-10-30 Amplimmune Inc human anti-b7-h4 antibodies and their uses.
EP2935332B1 (en) 2012-12-21 2021-11-10 MedImmune, LLC Anti-h7cr antibodies
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
CN115925957A (en) 2013-02-08 2023-04-07 Irm责任有限公司 Specific sites for modifying antibodies to make immunoconjugates
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9790478B2 (en) 2013-03-14 2017-10-17 Abbott Laboratories HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
CN105228649B (en) 2013-03-14 2019-01-18 雅培制药有限公司 HCV Ag-Ab combination measurement is with method and used in composition therein
EP3611189A1 (en) 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3
CA2903772A1 (en) 2013-03-15 2014-09-25 Novartis Ag Antibody drug conjugates
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
BR112015023797A2 (en) 2013-03-15 2017-10-24 Abbvie Inc dual specificity binding proteins directed against il-1b and / or il-17
CN106414489A (en) 2013-05-24 2017-02-15 米迪缪尼有限公司 Anti-b7-h5 antibodies and their uses
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
CA2914369C (en) 2013-06-06 2023-02-14 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
ES2753419T3 (en) 2013-06-07 2020-04-08 Univ Duke Complement factor H inhibitors
UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
JP2016533318A (en) 2013-09-17 2016-10-27 ユニバーシティ ヘルス ネットワーク （ユーエイチエヌ）： テクノロジー ディベロップメント アンド コマーシャリゼーション Agents targeting RGMA / neogenin cis interaction or lipid rafts and use of the agents in therapeutic methods
US10287572B2 (en) 2013-11-01 2019-05-14 Regents Of The University Of Minnesota Protein scaffolds and methods of use
TWI736515B (en) 2013-11-13 2021-08-21 美商輝瑞大藥廠 Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
US20150203592A1 (en) 2013-12-02 2015-07-23 Abbvie Inc. Compositions and methods for treating osteoarthritis
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
JP6533534B2 (en) 2014-02-14 2019-06-19 マクロジェニクス，インコーポレーテッド Composition for use in the treatment of glioblastoma and use thereof
EP3110974A4 (en) 2014-02-24 2018-01-24 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20150291689A1 (en) 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
AU2015229463A1 (en) 2014-03-12 2016-09-15 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
TW202214691A (en) 2014-03-21 2022-04-16 美商艾伯維有限公司 Anti-egfr antibodies and antibody drug conjugates
JP6832709B2 (en) 2014-05-16 2021-02-24 メディミューン，エルエルシー Molecules with modified neonatal Fc receptor binding for enhanced therapeutic and diagnostic properties
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
CN106456705A (en) * 2014-06-16 2017-02-22 硕腾服务有限责任公司 Intravaginal formulations comprising GnRH
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
WO2016011167A1 (en) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Her3 inhibition in low-grade serous ovarian cancers
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US10238748B2 (en) 2014-08-12 2019-03-26 Novartis Ag Anti-CDH6 antibody drug conjugates
PE20170894A1 (en) 2014-09-26 2017-07-12 Macrogenics Inc BI-SPECIFIC MONOVALENT DIACBODIES THAT ARE CAPABLE OF JOINING CD19 AND CD3 AND USING THE SAME
KR20170087500A (en) 2014-12-11 2017-07-28 피에르 파브르 메디카먼트 Anti-C10ORF54 antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
ES2784900T3 (en) 2014-12-12 2020-10-01 Massachusetts Gen Hospital Treatment of brain metastases from breast cancer
TW201639596A (en) 2015-01-24 2016-11-16 艾伯維有限公司 Compositions and methods for treating psoriatic arthritis
AU2015380455A1 (en) 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
WO2016120828A1 (en) 2015-01-30 2016-08-04 Novartis Ag Treatment of breast cancer by m-csf antagonist
AU2016227493B2 (en) 2015-03-03 2022-01-20 Kymab Limited Antibodies, uses & methods
RU2715597C2 (en) 2015-05-29 2020-03-02 Эббви Инк. Antibodies to cd40 and methods of use thereof
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
KR20180093127A (en) 2015-07-30 2018-08-20 마크로제닉스, 인크. PD-1-Binding Molecules and Methods of Use Thereof
CN116059340A (en) 2015-09-11 2023-05-05 艾伯维公司 Methods for treating relapsing forms of multiple sclerosis
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
IL258521B2 (en) 2015-10-08 2024-01-01 Macrogenics Inc Combination therapy for the treatment of cancer
WO2017070561A1 (en) 2015-10-23 2017-04-27 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
US10875920B2 (en) 2015-12-02 2020-12-29 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
TW201730212A (en) 2016-02-17 2017-09-01 宏觀基因股份有限公司 ROR1-binding molecules, and methods of use thereof
IL292946A (en) 2016-03-02 2022-07-01 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
US20170349653A1 (en) 2016-06-01 2017-12-07 Abbvie Inc. Methods for treating spinal cord injury and pain
LT3458479T (en) 2016-06-08 2021-02-25 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
BR112018075653A2 (en) 2016-06-08 2019-08-27 Abbvie Inc anti-b7-h3 antibodies and drug antibody conjugates
CA3027033A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CN109475603B (en) 2016-06-20 2023-06-13 科马布有限公司 anti-PD-L1 antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7274417B2 (en) 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド 4-1BB binding protein and uses thereof
WO2018111580A1 (en) 2016-12-13 2018-06-21 Emory University Polypeptides for managing viral infections
JOP20190155A1 (en) 2016-12-21 2019-06-23 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
AU2017382234A1 (en) 2016-12-23 2019-07-04 Macrogenics, Inc. ADAM9-binding molecules, and methods of use thereof
WO2018138297A1 (en) 2017-01-27 2018-08-02 Kymab Limited Anti-opg antibodies
JOP20190187A1 (en) 2017-02-03 2019-08-01 Novartis Ag Anti-ccr7 antibody drug conjugates
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
EP3612567A4 (en) 2017-04-19 2020-11-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
KR20200024158A (en) 2017-05-31 2020-03-06 주식회사 에스티큐브앤컴퍼니 How to treat cancer using antibodies and molecules that immunospecifically bind to BTN1A1
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
KR20200026209A (en) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand
SG11202003930YA (en) 2017-12-01 2020-05-28 Pfizer Anti-cxcr5 antibodies and compositions and uses thereof
JP2021508439A (en) 2017-12-01 2021-03-11 ノバルティス アーゲー Polyomavirus neutralizing antibody
CN112119092A (en) 2018-02-12 2020-12-22 无糖尿病公司 Improved antagonistic anti-human CD40 monoclonal antibodies
MX2020009526A (en) 2018-03-12 2020-10-28 Zoetis Services Llc Anti-ngf antibodies and methods thereof.
WO2019190984A1 (en) 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
US10640576B2 (en) 2018-04-10 2020-05-05 Y-Biologics Inc. Cell engaging binding molecules
CN112165974A (en) 2018-05-31 2021-01-01 诺华股份有限公司 Hepatitis B antibodies
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
IL279062B2 (en) 2018-06-01 2024-02-01 Eisai R&D Man Co Ltd Splicing modulator antibody-drug conjugates and methods of use
UY38265A (en) 2018-06-20 2020-01-31 Novartis Ag DRUG ANTIBODY CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS
US20210268070A1 (en) 2018-07-10 2021-09-02 Rush University Medical Center Use of Immunomodulators to Control Infection and Stimulate Healing in Normal and Diabetic Wounds
JP2021531007A (en) 2018-07-20 2021-11-18 ピエール、ファーブル、メディカマン Receptor for VISTA
SG11202100888WA (en) 2018-09-07 2021-02-25 Pfizer Anti-avb8 antibodies and compositions and uses thereof
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
KR20210102274A (en) 2018-12-13 2021-08-19 에자이 알앤드디 매니지먼트 가부시키가이샤 Herboxidiene Antibody-Drug Conjugates and Methods of Use
TW202039554A (en) 2018-12-19 2020-11-01 瑞士商諾華公司 Anti-tnf-alpha antibodies
CA3234463A1 (en) 2018-12-21 2019-12-18 Novartis Ag Antibodies to pmel17 and conjugates thereof
EP3911739A1 (en) 2019-01-16 2021-11-24 University Of Rochester Improvement of epithelial or endothelial barrier function
KR102563319B1 (en) 2019-03-08 2023-08-03 앱티스 주식회사 Site-specific antibody conjugation, and antibody-drug conjugate as its embodiment
AU2020279731A1 (en) 2019-05-20 2022-01-06 Novartis Ag Antibody drug conjugates having linkers comprising hydrophilic groups
WO2021062323A1 (en) 2019-09-26 2021-04-01 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
EP4055053A1 (en) 2019-11-07 2022-09-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
KR20220131293A (en) 2020-01-24 2022-09-27 화이자 인코포레이티드 Anti-E-Selectin Antibodies, Compositions and Methods of Use
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN115461363A (en) 2020-05-01 2022-12-09 诺华股份有限公司 Immunoglobulin variants
CN116096758A (en) 2020-05-01 2023-05-09 诺华股份有限公司 Engineered immunoglobulins
CA3180556A1 (en) 2020-05-29 2021-12-02 Stephan Becker Neutralizing antibodies against sars-related coronavirus
EP4161966A1 (en) 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
AU2021358662A1 (en) 2020-10-09 2023-05-04 Children's Medical Center Corporation CD1a ANTIBODIES AND USES THEREOF
GB202017058D0 (en) 2020-10-27 2020-12-09 Kymab Ltd Antibodies and uses thereof
MX2023005234A (en) 2020-11-06 2023-05-18 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies.
CN116472288A (en) 2020-11-06 2023-07-21 诺华股份有限公司 Antibody Fc variants
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
EP4251648A2 (en) 2020-11-24 2023-10-04 Novartis AG Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
EP4259200A1 (en) 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
GB202101125D0 (en) 2021-01-27 2021-03-10 Kymab Ltd Antibodies and uses thereof
CA3216880A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
WO2023073599A1 (en) 2021-10-28 2023-05-04 Novartis Ag Engineered fc variants
GB202117111D0 (en) 2021-11-26 2022-01-12 Kymab Ltd Antibodies for use as therapeutics against bacterial infections
WO2023099688A1 (en) 2021-12-01 2023-06-08 Universität Zu Köln Neutralizing antibodies against sars-related coronavirus
EP4190810A1 (en) 2021-12-01 2023-06-07 Universität zu Köln Neutralizing antibodies against sars-related coronavirus
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024028731A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors
WO2024028732A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002576A1 (en) * 1985-10-31 1987-05-07 Kv Pharmaceutical Company Vaginal delivery systems
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
EP0391342A1 (en) * 1989-04-05 1990-10-10 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
WO1994006457A1 (en) * 1992-09-17 1994-03-31 Synergen, Inc. Pharmaceutical formulations of interleukin-1 inhibitors
WO1996005321A1 (en) * 1994-08-17 1996-02-22 Rhone-Poulenc Rorer S.A. Gene therapy for restenosis using an adenoviral vector
WO1996010335A1 (en) * 1994-09-30 1996-04-11 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US501714A (en) * 1893-07-18 Pocket pencil-holder
EP0090837A1 (en) * 1981-10-08 1983-10-12 BERG, Kurt Frimann Method and composition for treating a patient suffering from interferonsusceptible disorder
AU5063885A (en) * 1984-10-23 1986-05-15 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
NZ222413A (en) * 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
US4810503A (en) 1987-03-31 1989-03-07 Basf Corporation Polymers which form gels at low concentrations in water
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
JPH03502574A (en) * 1987-12-03 1991-06-13 ザ　リポソーム　カンパニー，インコーポレイテッド Methylcellulose pharmaceutical composition
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5246698A (en) * 1990-07-09 1993-09-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
WO1993008845A1 (en) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
WO1987002576A1 (en) * 1985-10-31 1987-05-07 Kv Pharmaceutical Company Vaginal delivery systems
EP0391342A1 (en) * 1989-04-05 1990-10-10 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
WO1994006457A1 (en) * 1992-09-17 1994-03-31 Synergen, Inc. Pharmaceutical formulations of interleukin-1 inhibitors
WO1996005321A1 (en) * 1994-08-17 1996-02-22 Rhone-Poulenc Rorer S.A. Gene therapy for restenosis using an adenoviral vector
WO1996010335A1 (en) * 1994-09-30 1996-04-11 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986686B2 (en) 2002-06-14 2015-03-24 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9272032B2 (en) 2002-06-14 2016-03-01 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US9592293B2 (en) 2006-09-08 2017-03-14 Abbvie Inc. Interleukin-13 binding proteins
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US9481736B2 (en) 2009-03-05 2016-11-01 Abbvie, Inc. IL-17 binding proteins
US9403900B2 (en) 2009-08-13 2016-08-02 Crucell Holland B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
US9283274B2 (en) 2009-10-06 2016-03-15 Medimmune Limited RSV specific binding molecule
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9303085B2 (en) 2010-05-14 2016-04-05 Abbvie Inc. IL-1 binding proteins
US9409986B2 (en) 2010-05-14 2016-08-09 Abbvie Inc. IL-1 binding proteins
US9441038B2 (en) 2010-05-14 2016-09-13 Abbvie Inc. IL-1 binding proteins
US9447184B2 (en) 2010-05-14 2016-09-20 Abbvie Inc. IL-1 binding proteins
US9447183B2 (en) 2010-05-14 2016-09-20 Abbvie Inc. IL-1 binding proteins
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
US9139642B2 (en) 2010-07-09 2015-09-22 Crucell Holland B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US11849741B2 (en) 2015-10-20 2023-12-26 Savage River, Inc. Meat-like food products

Also Published As

Publication number Publication date
AU2063197A (en) 1997-09-22
EP0885002B1 (en) 2011-05-11
ATE508733T1 (en) 2011-05-15
WO1997032572A2 (en) 1997-09-12
US5985320A (en) 1999-11-16
ES2395214T3 (en) 2013-02-11
EP0885002A2 (en) 1998-12-23
PT885002E (en) 2011-07-14
DK0885002T3 (en) 2011-08-22
JP2000506165A (en) 2000-05-23

Similar Documents

Publication Publication Date Title
WO1997032572A3 (en) Materials and methods for enhancing cellular internalization
WO2000019978A3 (en) Compositions and methods for enhancing receptor-mediated cellular internalization
EP0993831A3 (en) Compounds and compositions for delivering active agents
CA2338358A1 (en) Compounds and compositions for delivering active agents
WO1998025613A3 (en) Galenic composition containing opioid antagonists
WO2000045792A8 (en) Hydrogel particle formulations
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
HUP0201243A2 (en) Glucocorticoid receptor modulators, pharmaceutical compositions containing them and their use
EP1244471A4 (en) Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
HUP0202810A3 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands, process for their preparation and pharmaceutical compositions containing them
HUP0003859A3 (en) Imidazole fused heterocyclic compounds, process for their preparation, pharmaceutical compositions containing the same and their use
GR3031246T3 (en) The use of glycerin in moderating transdermal drug delivery.
WO1999060119A3 (en) Multivalent t cell receptor complexes
AU6670998A (en) Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
MXPA01008611A (en) Compounds and compositions for delivering active agents.
HUP0101512A3 (en) Adhesive microsphere drug delivery composition, process for its preparation and device containing it
WO2000007543A8 (en) Conjugates targeted to the interleukin-2 receptors
IL74446A (en) Transdermal pharmaceutical compositions for systemic administration containing bopindolol or methysergide
CA2265678A1 (en) Electrotransport drug delivery reservoirs containing inert fillers
AU2001276831A1 (en) Delivery vehicle composition and methods for delivering antigens and other drugs
WO2000042031A3 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
HUP0200080A3 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists and pharmaceutical compositions containing the compounds
HUP0203847A3 (en) Substituted homopiperidinyl benzimidazole analogues as fundic relaxants, process for their preparation and pharmaceutical compositions containing them
IL136501A0 (en) Pharmaceutical compositions containing the leukotrpharmaceutical compositions containing the leukotriene antagonist zafirlukast, process for their preiene antagonist zafirlukast, process for their preparation and use thereof paration and use thereof
HUP9600333A3 (en) Azole derivatives as adhesive receptor antagonists, pharmaceutical compositions containing the same and process for their preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGE 25,DESCRIPTION,PAGE 27,CLAIMS,AND PAGES 1/7-7/7,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1997908818

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997908818

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA